Montelukast is a cysteinyl leukotriene receptor antagonist indicated for the management of persistent asthma in those aged ≥ years. Although it improves pulmonary function and symptoms ...

or leukotriene receptor antagonist (LTRA) maintenance therapy. Its primary endpoint was the time to the first severe asthma ...

"Montelukast, an orally active leukotriene receptor antagonist with anti-inflammatory effects, has been shown to suppress oxidative stress and cytokine production," the researchers wrote.